Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hailing Lu

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
BMC Cancer|November 3, 2011
The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancerTobias Hahn, Deborah J Bradley-Dunlop, Laurence H Hurley, et al.
BMC Cancer|May 19, 2023
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trialMengru Cao, Hailing Lu, Shi Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous MelanomaSylvia M Lee, Omid Hamid, Robert Jotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerMary L Disis, Danelle R Wallace, Theodore A Gooley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1Neeta Somaiah, Matthew S Block, Joseph W Kim, et al.
Clinical Immunology (Orlando, Fla.)|October 28, 2004
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)Jan Storek, Zhao Zhao, Eugene Lin, et al.
Oncoimmunology|December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Leukemia & Lymphoma|December 6, 2021
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphomaAhmad S Halwani, Carlos Panizo, Iris Isufi, et al.
Frontiers in Oncology|June 5, 2026
Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case seriesJessica S Zhang, Juliana C K Ng, Pedro Hermida de Viveiros, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
BMC Cancer|November 3, 2011
The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancerTobias Hahn, Deborah J Bradley-Dunlop, Laurence H Hurley, et al.
BMC Cancer|May 19, 2023
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trialMengru Cao, Hailing Lu, Shi Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous MelanomaSylvia M Lee, Omid Hamid, Robert Jotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerMary L Disis, Danelle R Wallace, Theodore A Gooley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1Neeta Somaiah, Matthew S Block, Joseph W Kim, et al.
Clinical Immunology (Orlando, Fla.)|October 28, 2004
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)Jan Storek, Zhao Zhao, Eugene Lin, et al.
Oncoimmunology|December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Leukemia & Lymphoma|December 6, 2021
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphomaAhmad S Halwani, Carlos Panizo, Iris Isufi, et al.
Frontiers in Oncology|June 5, 2026
Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case seriesJessica S Zhang, Juliana C K Ng, Pedro Hermida de Viveiros, et al.
Pageof 9